The startup develops targeted therapies and novel drug formulations specifically for pediatric oncology, focusing on the unique biological characteristics of childhood cancers. By commercializing these lifesaving treatments, the company aims to improve survival rates and quality of life for children and adolescents diagnosed with cancer.
Funding
$17M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pediatric cancers, while rare, remain a leading cause of death by disease among children, and many existing treatments are simply adult regimens adjusted for children, often leading to significant long-term health problems for survivors. The development of pediatric-specific cancer drugs faces challenges including the rarity of specific cancer types, the need for pediatric formulations, and limited financial investment.
Solution
Oncoheroes Biosciences is a biopharmaceutical company focused exclusively on discovering and developing new therapies for childhood cancers. The company in-licenses clinical-stage assets and conducts in-house research to identify novel oncogenic targets and drug combinations, utilizing a proprietary pediatric screening platform. Oncoheroes aims to accelerate regulatory approval and provide substantial benefits to pediatric patients by prioritizing projects related to cancer types with the highest prevalence and worst prognoses. They partner with industry, foundations, and patient associations to support the development of these novel therapies.
Target Audience
The primary target audience includes children and adolescents with cancer, pediatric oncologists, and their families, as well as pharmaceutical companies, foundations, and patient associations involved in pediatric cancer research and treatment.
Features
- Focus on pediatric cancer types with the highest prevalence and worst prognosis, including Diffuse Intrinsic Pontine Glioma (DIPG), Atypical Teratoid Rhabdoid Tumor (ATRT), and others.
- Proprietary pediatric screening platform to identify and characterize new oncogenic pathways.
- In-licensing of clinic-ready assets for fast-track regulatory approval.
- Clinical development team with a comprehensive strategy for identifying promising pediatric cancer drug candidates.
- Pipeline includes Volasertib (Phase II/III for Alveolar Rhabdomyosarcoma) and Dovitinib (Preclinical for Osteosarcoma).
- Actively identifying and evaluating additional assets for in-licensing.